RxDoctor Payments Data

Amy Cheney, MD

Interventional Cardiology · Seattle, WANPI 1396002507

Payments from drug & device makers

What this record shows

This record is dominated by grants: $30,000 of the $30,874 with a category attached, or 97.2%. Boston Scientific accounts for 97.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $30,000 and has fallen 98.6% since, to $419 in 2025.

$30,874in general payments, 2019–2025

Across 15 payments — averaging $2058.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$30K
  • Abiomed$324
  • Teleflex LLC$175
  • Shockwave Medical, Inc$166
  • Medtronic$110
  • AstraZeneca$72
  • plus $13 from 1 others

What the payments were for

  • Grants$30,00097%
  • Food & beverage$8743%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,874 in reported general payments places this provider in the 85th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$121,449
Medicare patients
349
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$101,307
Repatha SureclickEvolocumab28$20,723
XareltoRivaroxaban12$20,035
Repatha PushtronexEvolocumab27$17,168
BrilintaTicagrelor17$14,410
Metoprolol Succinate101$1,594
Atorvastatin Calcium158$1,189
Rosuvastatin Calcium54$984
Ezetimibe39$645
Losartan Potassium58$577
Carvedilol51$558
ClopidogrelClopidogrel Bisulfate30$421
Amlodipine Besylate45$237
Omega-3 Acid Ethyl Esters11$227
Hydralazine Hcl13$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$72$14,41017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →